Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EC HealthcareUNHLF 54 Debt-to-EBITDA is -4.50 as of Mar. 2026. GuruFocus rates UNHLF with a GF Score™ of 54/100 and a GF Value™ of $0.16. The stock has 5 warning signs investors should review. Among 478 Healthcare Providers & Services companies, EC Healthcare ranks worse than 85.15% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for EC Healthcare's Debt-to-EBITDA or its related term are showing as below:
UNHLF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 1.62 Max: 7.24
Current: 7.24
During the past 12 years, the highest Debt-to-EBITDA Ratio of EC Healthcare was 7.24. The lowest was 0.00. And the median was 1.62.
UNHLF's Debt-to-EBITDA is ranked worse than 85.15% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.185
vs UNHLF: 7.24
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
EC Healthcare Debt-to-EBITDA Related Terms
EC Healthcare Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for EC Healthcare's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, EC Healthcare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EC Healthcare Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, EC Healthcare's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where EC Healthcare's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
EC Healthcare (UNHLF) has a Debt-to-EBITDA of -4.50 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on EC Healthcare. According to the industry distribution chart, EC Healthcare ranks #407 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 85.1%.
Is EC Healthcare's Debt-to-EBITDA too high?
EC Healthcare's current Debt-to-EBITDA is -4.50. Based on the distribution chart, EC Healthcare ranks #407 out of 478 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, EC Healthcare has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does EC Healthcare's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, EC Healthcare ranks #407 out of 478 companies for Debt-to-EBITDA. This places EC Healthcare in the lower half of its industry. The industry median Debt-to-EBITDA is 2.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on EC Healthcare. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EC Healthcare's current Debt-to-EBITDA is -4.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EC Healthcare stock overvalued right now?
EC Healthcare (UNHLF) has a current Debt-to-EBITDA of -4.50. The stock's GF Value™ is $0.16, compared to a current price of $0.09 — trading 46.3% below its estimated fair value. The current Debt-to-EBITDA is -4.50. EC Healthcare's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For EC Healthcare (UNHLF), the current Debt-to-EBITDA is -4.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EC Healthcare (UNHLF) Overvalued in 2026?
Based on GuruFocus' analysis, EC Healthcare stock appears to be undervalued.
The current stock price of $0.09 is trading 46.3% below its estimated GF Value™ of $0.16.
Key valuation signals for UNHLF:
Debt-to-EBITDA: -4.50
GF Value™: $0.16 vs. price of $0.09 (46.3% below fair value)
No single metric tells the full story. See the UNHLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EC Healthcare is a Hong Kong-based non-hospital medical service provider. The principal activities of the group include the provision of medical services; aesthetic medical services, comprising medical aesthetics and dental services; beauty and wellness services, comprising traditional beauty, haircare, and ancillary wellness services; and the sale of skincare, healthcare, and beauty products. The group caters to its services through the operating segments of Medical, which is the key revenue generator segment and Aesthetic medical, beauty and wellness, Veterinary, and others. Geographically, the group has a business presence in Hong Kong, Macau, Mainland China, and Taiwan. It generates the majority of its revenue from Hong Kong.
54GF Score
Get the complete analysis for UNHLF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UNHLF has been successfully added to your 
